[Nuclear oncology with monoclonal antibodies and peptides].
Imaging and therapy using radiolabeled monoclonal antibodies have proved useful in many clinical studies. However, immunogenicity of mouse antibodies to human and insufficient tumor-to-normal tissue ratios remained to be solved. Chimerization and humanization by genetic engineering, and multistep targeting techniques have enabled lower immunogenicity and higher tumor-to-normal tissue contrast. Peptides like somatostatin-analogs have been reportedly useful in imaging tumors, which are either somatostatin receptor positive or negative. Elevated normal tissue accumulation of radiolabeled peptides is a drawback in aiming internal radiation therapy.
Hosono
M
M
Department of Radiology, Saitama Medical Center, Saitama Medical School.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D014660:Vasoactive Intestinal Peptide / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; C114933:octreotide, iodoTyr(3)-; C071632:SDZ 215-811; D014660:Vasoactive Intestinal Peptide; D004369:Pentetic Acid; D015282:Octreotide